Emerging drugs in the treatment of chronic cough

INTRODUCTION Chronic cough is a debilitating condition that is among the most common reasons for seeking medical attention yet remains challenging to manage. Identifying an underlying respiratory, nasal or upper gastrointestinal disease triggering cough is the first step in assessment, but once this has been ruled out or adequately treated, many patients remain troubled with chronic cough. AREAS COVERED This narrative review discusses the role of existing treatments and describes the current research landscape for the development of new therapies for chronic cough greater than 8 weeks that is refractory (RCC) or unexplained (UCC). The literature search includes published studies found on pubmed and conference abstracts until 2023. EXPERT OPINION RCC/UCC can occur due to neuronal dysregulation of the vagus nerve or central nervous system. Hence, novel anti-tussives have targeted ion channels involved in the neuronal signaling which triggers cough. Although some therapies targeting receptors such as TRPV1 have failed to show efficacy, P2X3 antagonists have emerged as the most promising therapy for patients impacted by chronic cough. Disease specific therapies such as for idiopathic pulmonary fibrosis are in early development.

[1]  J. Smith,et al.  Mini-review: Hypertussivity and allotussivity in chronic cough endotypes , 2022, Neuroscience Letters.

[2]  S. Birring,et al.  A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough , 2022, Lung.

[3]  Augustine S. Lee,et al.  A double-blind randomised placebo-controlled trial investigating the effects of lesogaberan on the objective cough frequency and capsaicin-evoked coughs in patients with refractory chronic cough , 2022, ERJ Open Research.

[4]  S. Spechler,et al.  ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. , 2021, The American journal of gastroenterology.

[5]  T. Kamei,et al.  Randomised trial of the P2X3 receptor antagonist sivopixant for refractory chronic cough , 2021, European Respiratory Journal.

[6]  K. Delucchi,et al.  Latent Class Analysis-Derived Subphenotypes are Generalizable to Observational Cohorts of Acute Respiratory Distress Syndrome: A Prospective Study , 2021, Thorax.

[7]  J. Smith,et al.  An open-label study of the tolerability and potential efficacy of memantine for treating refractory chronic cough , 2021, ERJ Open Research.

[8]  J. Smith,et al.  Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial , 2021, Pulmonary Therapy.

[9]  B. Forsberg,et al.  Prevalence, progression and impact of chronic cough on employment in Northern Europe , 2020, European Respiratory Journal.

[10]  J. Smith,et al.  A Randomized Controlled Trial to Assess the Effect of Lidocaine Administered via Throat Spray and Nebulization in Patients with Refractory Chronic Cough. , 2020, The journal of allergy and clinical immunology. In practice.

[11]  M. Farrell,et al.  Behavioral and regional brain responses to inhalation of capsaicin modified by painful conditioning in humans. , 2020, Chest.

[12]  J. Smith,et al.  Allergen challenge increases capsaicin-evoked cough responses in patients with allergic asthma. , 2019, The Journal of allergy and clinical immunology.

[13]  A. Morice,et al.  The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study , 2019, European Respiratory Journal.

[14]  J. Smith,et al.  The Neurokinin-1 Receptor Antagonist Orvepitant is a Novel Antitussive Therapy for Chronic Refractory Cough: Results from a Phase 2 Pilot Study (VOLCANO-1). , 2019, Chest.

[15]  M. Cazzola,et al.  Bronchodilator therapy for chronic cough. , 2017, Pulmonary pharmacology & therapeutics.

[16]  T. Buday,et al.  TRPV4 antagonist GSK2193874 does not modulate cough response to osmotic stimuli , 2017, Respiratory Physiology & Neurobiology.

[17]  J. Smith,et al.  Chronic Cough Due to Gastroesophageal Reflux in Adults: CHEST Guideline and Expert Panel Report. , 2016, Chest.

[18]  S. Birring,et al.  Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial , 2016, Thorax.

[19]  B. Undem,et al.  Vagal Afferent Innervation of the Airways in Health and Disease. , 2016, Physiological reviews.

[20]  S. Birring,et al.  Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized Controlled Trial. , 2016, Chest.

[21]  D. Smallwood,et al.  Neural correlates of cough hypersensitivity in humans: evidence for central sensitisation and dysfunctional inhibitory control , 2016, Thorax.

[22]  M. Kollarik,et al.  Cough reflex sensitization from esophagus and nose. , 2015, Pulmonary pharmacology & therapeutics.

[23]  A. Morice,et al.  The global epidemiology of chronic cough in adults: a systematic review and meta-analysis , 2015, European Respiratory Journal.

[24]  S. Birring,et al.  Expert opinion on the cough hypersensitivity syndrome in respiratory medicine , 2014, European Respiratory Journal.

[25]  J. Smith,et al.  Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: a double-blind randomized controlled trial. , 2014, The Journal of allergy and clinical immunology.

[26]  J. Shim,et al.  A systematic review of symptomatic diagnosis of lung cancer. , 2014, Family practice.

[27]  J. Smith,et al.  Antitussive effects of memantine in guinea pigs. , 2012, Chest.

[28]  M. Lougheed,et al.  Cough in asthma. , 2011, Current opinion in pharmacology.

[29]  C. T. French,et al.  A prospective global measure, the Punum Ladder, provides more valid assessments of quality of life than a retrospective transition measure. , 2010, Journal of clinical epidemiology.

[30]  B. Canning.  Afferent nerves regulating the cough reflex: mechanisms and mediators of cough in disease. , 2010, Otolaryngologic clinics of North America.

[31]  Y. Takeuchi,et al.  The importance of basidiomycetous fungi cultured from the sputum of chronic idiopathic cough: a study to determine the existence of recognizable clinical patterns to distinguish CIC from non-CIC. , 2009, Respiratory medicine.

[32]  M. Kollarik,et al.  Mechanisms of the cough associated with rhinosinusitis. , 2009, Pulmonary pharmacology & therapeutics.

[33]  P. Chazot,et al.  NMDA receptor subtypes: Structure, function and therapeutics , 2008 .

[34]  David Julius,et al.  The menthol receptor TRPM8 is the principal detector of environmental cold , 2007, Nature.

[35]  A. Jeyakumar,et al.  Effectiveness of Amitriptyline Versus Cough Suppressants in the Treatment of Chronic Cough Resulting From Postviral Vagal Neuropathy , 2006, The Laryngoscope.

[36]  D. Theodoros,et al.  Efficacy of speech pathology management for chronic cough: a randomised placebo controlled trial of treatment efficacy , 2006, Thorax.

[37]  R. Irwin,et al.  The New “Face” of CHEST Heralds a New Era , 2006 .

[38]  K. J. Macleod,et al.  Effect of inhaled corticosteroids on symptom severity and sputum mediator levels in chronic persistent cough. , 2004, The Journal of allergy and clinical immunology.

[39]  D. Weinreich,et al.  Subtypes of vagal afferent C‐fibres in guinea‐pig lungs , 2004, The Journal of physiology.

[40]  Sally J. Singh,et al.  Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ) , 2003, Thorax.

[41]  S. Subburaj,et al.  Application and validation of a computerized cough acquisition system for objective monitoring of acute cough: a meta-analysis. , 2001, Chest.

[42]  A J Wardlaw,et al.  Eosinophilic bronchitis is an important cause of chronic cough. , 1999, American journal of respiratory and critical care medicine.

[43]  E. Araújo,et al.  A pathogenic triad in chronic cough: asthma, postnasal drip syndrome, and gastroesophageal reflux disease. , 1999, Chest.

[44]  F. Hargreave,et al.  Nonasthmatic chronic cough: No effect of treatment with an inhaled corticosteroid in patients without sputum eosinophilia. , 1999, Canadian respiratory journal.

[45]  R. Irwin,et al.  Impact of chronic cough on quality of life. , 1998, Archives of internal medicine.

[46]  K. Rauf,et al.  Inhibition of Capsaicin‐Induced Cough by the γ‐Aminobutyric Acid Agonist Baclofen , 1998 .

[47]  L. Boulet,et al.  Airway inflammation in nonasthmatic subjects with chronic cough. , 1994, American journal of respiratory and critical care medicine.

[48]  R. Irwin,et al.  Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. , 1990, The American review of respiratory disease.